CN1684705A - 使用具有preptin功能的化合物的方法 - Google Patents

使用具有preptin功能的化合物的方法 Download PDF

Info

Publication number
CN1684705A
CN1684705A CNA03823520XA CN03823520A CN1684705A CN 1684705 A CN1684705 A CN 1684705A CN A03823520X A CNA03823520X A CN A03823520XA CN 03823520 A CN03823520 A CN 03823520A CN 1684705 A CN1684705 A CN 1684705A
Authority
CN
China
Prior art keywords
preptin
seq
asp
agonist
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA03823520XA
Other languages
English (en)
Chinese (zh)
Inventor
G·J·S·库珀
C·M·比沙南
G·C·詹姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protemix Corp Ltd
Original Assignee
PUROTMIX Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PUROTMIX Ltd filed Critical PUROTMIX Ltd
Publication of CN1684705A publication Critical patent/CN1684705A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
CNA03823520XA 2002-08-01 2003-08-01 使用具有preptin功能的化合物的方法 Pending CN1684705A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40044502P 2002-08-01 2002-08-01
NZ52053602 2002-08-01
NZ520536 2002-08-01
US60/400,445 2002-08-01

Publications (1)

Publication Number Publication Date
CN1684705A true CN1684705A (zh) 2005-10-19

Family

ID=31497753

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA03823520XA Pending CN1684705A (zh) 2002-08-01 2003-08-01 使用具有preptin功能的化合物的方法

Country Status (6)

Country Link
EP (1) EP1534321A1 (ja)
JP (1) JP2006500341A (ja)
CN (1) CN1684705A (ja)
AU (1) AU2003258895A1 (ja)
CA (1) CA2494308A1 (ja)
WO (1) WO2004012761A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324234A (zh) 1998-09-25 2001-11-28 格利科克斯有限公司 果糖胺氧化酶,拮抗剂和抑制剂
EP1487431B1 (en) 2002-03-08 2012-05-02 PhilERA New Zealand Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
JP2006503014A (ja) 2002-08-20 2006-01-26 プロテミックス コーポレイション リミティド 剤形及び関連する治療法
CA3050047A1 (en) 2004-07-19 2006-03-16 Philera New Zealand Limited Synthesis of triethylenetetramines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078805A1 (en) * 1999-06-18 2000-12-28 Protemix Corporation Limited Peptide having preptin functionality

Also Published As

Publication number Publication date
WO2004012761A1 (en) 2004-02-12
EP1534321A1 (en) 2005-06-01
JP2006500341A (ja) 2006-01-05
CA2494308A1 (en) 2004-02-12
AU2003258895A1 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
US5756461A (en) Methods for treating diabetes
US5521283A (en) Anti-obesity proteins
CN110546161B (zh) 对胰岛素受体具有降低的结合力的胰岛素类似物及其用途
TW200520772A (en) Muteins of fibroblast growth factor 21
AU676891B2 (en) Pharmaceutical containing the P40 subunit of interleukin 12
JPH01501283A (ja) 新規な型のコロニー刺激因子―1
JP2009539805A (ja) 安定化されたインスリン様増殖因子ポリペプチド
JPH03198792A (ja) ヒトエリスロポエチンの生産方法
CN1655675A (zh) 利用三叶肽的联合治疗
EP0456642A1 (en) Somatotropin analogs
CN1040741A (zh) 抗酸成纤维细胞生长因子复合物及其治疗胃肠道遗疡病的方法
CN1202112A (zh) 增强胰腺功能的组合物
US6660257B1 (en) Circular permuteins of flt3 ligand
CN1737150A (zh) 脂联素-胰升糖素样肽-1类似肽融合蛋白表达载体及构建
JPH11505706A (ja) 肥満症遺伝子産物
CN1684705A (zh) 使用具有preptin功能的化合物的方法
WO1998038304A1 (fr) Nouveau polypeptide, adn le codant et utilisation de ce polypeptide
CN1973898A (zh) 一种含p28分子或其基因的医药制剂
US20040142393A1 (en) Methods of use of compounds with preptin function
MXPA04006676A (es) Variantes de prolactina de mamifero.
CN1160721A (zh) 成纤维细胞生长因子-2结构类似物,其生产方法及应用
CN1239516C (zh) 肿瘤坏死因子相关细胞凋亡诱导配体胞外区突变多肽及其制法与用途
CN1289527C (zh) 一种高生物活性的角质细胞生长因子突变体,其制备方法及用途
WO2024152259A1 (zh) 具有三重活性的融合蛋白及其应用
EP0363063A2 (en) Sheep growth hormone

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: PROT MEEKS FOUND CO., LTD.

Free format text: FORMER OWNER: PUROTMIX LTD.

Effective date: 20060324

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20060324

Address after: Oakland, New Zealand

Applicant after: Protemix Corp. Ltd.

Address before: Oakland, New Zealand

Applicant before: Purotmix Ltd.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication